Molecule
- Glimepiride (2 mg): A sulfonylurea that stimulates insulin release from pancreatic beta cells.
- Metformin Hydrochloride (500 mg SR): A biguanide that reduces glucose production in the liver and improves insulin sensitivity.
- Voglibose (0.2 mg): An alpha-glucosidase inhibitor that delays carbohydrate digestion, reducing postprandial blood glucose levels.
Category
Anti-Diabetic Medication – 3rd gen SU+Biguanide+Alpha-glucosidase inhibitor.
Glimepiride 2 mg + Metformin Hydrochloride 500 mg SR + Voglibose 0.2 mg
Glimihar-MV2 is an advanced triple-combination oral hypoglycemic agent containing Glimepiride (2 mg), Metformin Hydrochloride (500 mg SR), and Voglibose (0.2 mg). This formulation provides comprehensive glycemic control for Type 2 Diabetes Mellitus patients by enhancing insulin secretion, improving insulin sensitivity, and delaying carbohydrate absorption to prevent postprandial blood glucose levels.
Benefits
✔ Better blood sugar regulation
✔ Enhances insulin sensitivity
✔ Sustained glucose control
Storage & Precautions
- Store below 30°C, away from moisture
- Not for patients with severe renal or hepatic issues
- Avoid alcohol consumption
Packaging
10 x 10 Tablets per box
For medical use only. Consult a doctor before use.